Modern Slavery Statement 2016/17

Cancer Research UK is committed to continuously improving its high standards to combat slavery and human trafficking in its business and supply chain, and in acting ethically and with integrity in its business relationships.

This statement is made pursuant to section 54 of the Modern Slavery Act 2015. It constitutes Cancer Research UK’s slavery and human trafficking statement for the financial year ended 31 March 2017. It covers the activities of Cancer Research UK and its wholly-owned subsidiaries: Cancer Research UK Trading Limited and Cancer Research Technology Limited.

Our Organisation
Cancer Research UK is the world’s largest cancer charity dedicated to saving lives through research. We rely on the generosity of the public to fund this research through donations, buying goods in our shops or online and taking part in a wide range of fundraising events.

We have around 3,500 staff and over 40,000 volunteers, most of whom are based in the United Kingdom. Our staff are largely directly employed and are not in any category which is generally seen to be vulnerable to modern slavery in this country, so our focus is to ensure there are policies and procedures in place for our contractors and suppliers.

Our Supply Chain
Cancer Research UK uses a wide range of suppliers who supply goods for sale, provide services at events and support our operations.

Having reviewed our business operations and relationships, we believe that the area of highest modern slavery risk is in the supply chain supporting the procurement of goods and materials for our fundraising and marketing activity and for resale in our network of charity shops, particularly where those suppliers are in high risk countries and/or manufacturing goods.

Due Diligence
Cancer Research UK carries out comprehensive due diligence on suppliers in high risk areas and has developed very clear and robust procedures for assessing and auditing those suppliers. This ensures that we only select suppliers who comply with our high standards and policies.

All suppliers which we class as high risk must:

 - Complete a Modern Slavery Act Due Diligence questionnaire which covers their governance, policies, training and supply chains management processes; and
 - Provide a full and complete list of all sites they are proposing to commission goods from on behalf of Cancer Research UK on an annual basis.

All manufacturing sites must then provide an annual Independent Ethical Audit to ensure ethical standards and full transparency are maintained.

Cancer Research UK has an internal team responsible for assessing information and documentation submitted by suppliers. Should a supplier fail or refuse to provide the information required or meet Cancer Research UK’s expectations, this may result in Cancer Research UK not entering into a relationship with them or terminating any current relationship.


Cancer Research UK has a number of policies which aim to minimise the risk of modern slavery in our supply chain. These include:

 - Working with Suppliers and Partners Policy which sets out internal requirements for buying goods and services;
 - Responsible Procurement Policy covering issues of human rights, child and forced labour and modern slavery, which Cancer Research UK’s suppliers are required to comply with; and
 - Whistleblowing Policy which encourages staff to report any concerns including any related to modern slavery/trafficking and child and forced labour.

During the year, training was provided to those teams who have direct responsibility for relevant supply chain management. We also developed a Modern Slavery Act Guidance document which is available to staff through Cancer Research UK’s intranet.

Looking Ahead
We will continue to review our procurement process and engage with our suppliers. We also plan to review our Responsible Procurement Policy and will provide further training on modern slavery as appropriate.

This statement has been approved by the Trustees of Cancer Research UK and the Directors of Cancer Research UK Trading Limited and Cancer Research Technology Limited and signed on their behalf.